跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HER2-CAR T-cells
首页
药物
HER2-CAR T-cells
HER2-CAR T-cells
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
UNIVERSAL IMMUNE CELLS FOR CANCER IMMUNOTHERAPY
EP 3250695 B1
申请人: BAYLOR COLLEGE MEDICINE
优先权: 2015
EP
US
WO
7 件公开
T-CELLS COMPRISING TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
EP 3720882 A4
申请人: MEDICAL RES INFRASTRUCTURE & HEALTH SERVICES FUND TEL AVIV MEDICAL CT
优先权: 2017
EP
US
WO
4 件公开
Anti-tumor drug combination and application thereof
CN 119971030 A
申请人: NANKAI INTERNATIONAL ADVANCED RES INSTITUTE SHENZHEN FUTIAN
优先权: 2025
CN
2 件公开
CAR-T cell as well as preparation method and application thereof
CN 106047817 A
申请人: SHENZHEN ISTEM REGENERATIVE MEDICINE SCI-TECH CO LTD
优先权: 2016
CN
Infection mixture and preparation method thereof
CN 106222200 A
申请人: SHENZHEN ISTEM REGENERATIVE MEDICINE SCI-TECH CO LTD
优先权: 2016
CN
CAR-T vector capable of targeting Her2 and blocking PD-L1 to reduce tumor immune escape and construction method and use thereof
CN 108203720 A
申请人: SHANGHAI SHENGBO BIOMEDICAL TECH CO LTD
优先权: 2016
CN
CAR-T vector capable of targeting Her2 and disturbing PD-L1 to reduce tumor immune escape and construction method and use thereof
CN 108203717 A
申请人: SHANGHAI SHENGBO BIOMEDICAL TECH CO LTD
优先权: 2016
CN
HER2 CAR recombinant lentiviral vector and construction method and application thereof
CN 106749678 A
申请人: BEIJING PREGENE TECH CO LTD
优先权: 2017
CN
PD1-knockout chimeric antigen receptor T cell targeting HER2, preparation method and application thereof
CN 109837304 A
申请人: SHENZHEN BINDEBIO TECH CO LTD
优先权: 2017
CN
Targeting antitumor T cell as well as preparation method and application thereof
CN 110144326 A
申请人: SHENZHEN BINDE BIOTECHNOLOGY CO LTD
优先权: 2018
CN
第 1 / 4 页
上一页
下一页
药物
反馈